Valneva Announces the Availability of Documentation for its Shareholder Meeting
31 Mai 2023 - 07:00AM
GlobeNewswire Inc.
Saint-Herblain
(France),
May
31,
2023 – Valneva
SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
company, today announced the availability of documentation for its
Combined General Meeting to be held on June 21, 2023 at 2 p.m.
CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai
Jules Courmont, 69002 Lyon (France).
The preliminary Notice of Meeting, containing
the agenda, the draft resolutions and instructions for
participation and voting, was published in the French Bulletin des
Annonces Légales Obligatoires (BALO) on May 15, 2023.
Documents and information relating to the
Meeting are available on Valneva’s website (www.valneva.com) in the
“Investors/General Meetings” section. Shareholders can also obtain
the Combined General Meeting documents upon request to the Company
by sending an email to the following address:
assemblee.generale@valneva.com.
The Company also recommends that shareholders
regularly consult the Combined General Meeting section of its
website, www.valneva.com.
Contact Details, Legal
DepartmentValneva SEService Assemblée Générale6 rue Alain
Bombard, 44800 Saint-Herblain
(France)assemblee.generale@valneva.com
| Media
& Investor ContactsLaëtitia Bachelot-FontaineVP Global
Communications & European Investor RelationsM +33 (0)6 4516
7099
laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
About Valneva SEWe are a
specialty vaccine company focused on the development, manufacturing
and commercialization of prophylactic vaccines for infectious
diseases. We take a highly specialized and targeted approach to
vaccine development by focusing on vaccine solutions addressing
unmet medical needs to ensure we can make a difference to peoples’
lives. We apply our deep understanding of vaccine science,
including our expertise across multiple vaccine modalities, and our
established vaccine development capabilities, to develop vaccines
against diseases which are not yet vaccine-preventable, or for
which there are limited effective treatment options. Today, we are
leveraging our expertise and capabilities to rapidly advance a
broad range of vaccines into and through the clinic, including
candidates against the chikungunya virus and Lyme disease.
- 2023_05_31_AGM_Availability_of_Documents_PR_EN_Final
Valneva (EU:VLA)
Graphique Historique de l'Action
De Août 2023 à Sept 2023
Valneva (EU:VLA)
Graphique Historique de l'Action
De Sept 2022 à Sept 2023
